Anti-USAG-1 antibody (TRG-035)

1What an anti-USAG-1 antibody actually is

An antibody is a large folded protein whose whole function is to recognise one shape and hold on to it. A neutralising antibody does that to something you want removed from the conversation: it binds the target in the tissue and takes it out of play. An anti-USAG-1 antibody does exactly this to USAG-1 — the secreted antagonist that quietens BMP signalling wherever it is made.

The therapeutic logic is subtractive rather than additive. Nothing foreign is instructed to happen; a suppressor is lifted, and the biology that resumes is the animal’s own conserved tooth-building programme. Mouse genetics established the principle first — animals lacking functional USAG-1 grow supernumerary teeth² — and the antibody reproduces that state pharmacologically rather than genetically. A separate line of work has shown the same target can be hit with a different modality entirely: local Usag-1 siRNA promoted tooth development in Runx2-deficient mice⁹.

2The selectivity decision — the BMP arm, not LRP5/6

USAG-1 is not a single-purpose blocker. It works on two arms at once: it binds BMP molecules directly so they cannot dock on their receptors, and it interacts with LRP5/6, the co-receptor through which Wnt signals are read³⁴. That dual character is why a crude anti-USAG-1 antibody would be the wrong drug: LRP5/6 is the trunk line of canonical Wnt signalling, and interfering with it body-wide is a very different proposition from lifting a local BMP brake.

Read that sentence slowly and it stops being a footnote and becomes the specification. The therapeutic effect is not attributed to “blocking USAG-1”; it is attributed to blocking one of its two interfaces. Selecting for that discrimination is the engineering that turns a target into a molecule — and it is the reason a page about USAG-1 biology and a page about the antibody are not the same page.

3TRG-035 — the drug profile in brief

Every field below is transcribed from the Japanese clinical-trials registry record jRCT2051240154, fetched live on 6 September 2026, or from Toregem BioPharma’s own announcements. Nothing here is taken from a secondary description of either.

4Immunogenicity — the endpoint the registry itself measures

The most commonly asked hard question about any antibody drug — will the body start attacking the medicine? — has a registry-anchored answer here, because the trial was designed to ask it. Among the secondary outcomes, verbatim: “Pharmacokinetics, frequency of serum anti-TRG035 antibody”.

An anti-drug antibody is the recipient’s own immune response raised against a therapeutic protein. It matters for two reasons that have nothing to do with each other: it can clear the drug faster than intended, blunting the effect, and it can itself provoke a reaction. Measuring its frequency in a first-in-human single-dose study is the standard first look — it establishes whether the response happens at all and roughly how often, not what repeat dosing would do.

That distinction is the honest boundary of what a single-dose design can deliver. A single administration cannot describe the behaviour of a molecule given repeatedly, which is the setting in which anti-drug antibodies usually matter most. No immunogenicity results are posted in the registry record as of 6 September 2026.

5Beyond teeth — the kidney and bone stakes

USAG-1 was not discovered in a tooth. It was characterised as a BMP antagonist abundantly expressed in the kidney⁶, where it was then reported to accelerate tubular injury⁵. Through its kinship with sclerostin it also sits in bone biology. So an antibody given intravenously does not meet its target only where a tooth is wanted — it meets it everywhere USAG-1 is made. That is the systemic question, and it is the one no consumer-facing page about tooth regrowth tends to raise.

What makes it genuinely interesting is that the kidney literature does not point in one direction only. In 2026, USAG-1 was reported to aggravate renal ischaemia–reperfusion injury by promoting GPX4 degradation-induced ferroptosis⁷. In that model, removing USAG-1 is protective, not harmful. The correct statement is therefore not “systemic blockade is dangerous” and not “systemic blockade is fine” — it is that the systemic consequences of neutralising USAG-1 in a human being are unestablished in both directions, and that an active renal literature is still moving.

The closest available precedent is not in dentistry at all. Sclerostin is USAG-1’s nearest structural relative in the same secreted cystine-knot family, and an antibody against sclerostin has already been carried through large randomised fracture trials in humans¹⁰¹¹. What that precedent does and does not transfer is set out on the selectivity page →.

6Who else is developing an anti-USAG-1 antibody

A search of the ClinicalTrials.gov v2 API on 6 September 2026 for the strings TRG035, TRG-035 and anti-USAG-1 returned zero interventional studies. The two records returned for the bare strings USAG-1 and SOSTDC1 are a frailty programme matching the unrelated acronym WISE, which happens to be one of USAG-1’s protein aliases — a false positive, not a second programme.

On that evidence: no second anti-USAG-1 antibody programme was identified in the sources searched for this record, and the only registry record identified for the molecule is the Japanese jRCT2051240154. That is a scoped statement about the registries and literature searched here on one date — not a claim that none exists anywhere. Where competition does appear against the same target, it appears as a different modality rather than a rival antibody: local Usag-1 siRNA in mice⁹.

7Evidence atlas — every load-bearing claim, tiered

Each claim this record leans on, with the tier of evidence behind it and the source it came from. The tiers are kept visibly separate and never averaged together: a registry field and a mouse experiment are both real, and they are not the same kind of fact.

8The target itself, in one card

This record is about the antibody. The target it binds has its own record, and the depth belongs there rather than being restated here in a second, separately maintained copy. What follows is the minimum needed to read this page.

Locus re-verified against the NCBI Gene record for SOSTDC1 (Gene ID 25928) on 6 September 2026: map location 7p21.2. An earlier version of this page printed 7p21.1; that was a defect, it was corrected, and the correction is recorded here rather than quietly overwritten.

9Panacea Bio Chem’s angle

The biology of USAG-1 is being mapped quickly. The quieter problem sits downstream of the discovery: an anti-USAG-1 antibody is itself a fragile folded protein, and a therapeutic antibody only works while it keeps the exact shape that lets it recognise its target. On this molecule that is not an abstraction — the entire therapeutic effect rests on discriminating between two interfaces of one small protein, and a fold that has drifted is a fold that discriminates less well. Drying to a shelf-stable form, months of storage, and reconstitution at the point of care can each unfold, oxidise or aggregate an antibody, turning an elegant molecular key into an inert clump.

10The story — the teeth we stopped growing